Main Article Content
Background: Neuropathic pain is defined by International Association for the Study of Pain (IASP) as “Pain caused by a lesion or disease of the somatosensory nervous system”. Elderly patients generally have high incidence of chronic neuropathic pain. The safe and effective treatment for chronic pain is a large public health concern. Palmitoylethanolamide (PEA) is an endogenously produced amide cannabimimetic compound with tissue protection and anti-inflammatory activity. Objectives: The aim & objective of this study is to evaluate the effectiveness and safety of Palmitoylethanolamide (PEA) in patients suffering from Neuropathic/Chronic Pain. Study Designed: Prospective Study. Materials and Methods: The Study was conducted in the Neurosurgery unit of Surgery Department in Gandhi Medical College & Associated Hamidia Hospital, Bhopal. A total no. of 150 patients aged 20-78 years were included in the study and divided into two groups, group I (Study group) and the group II (Control group) PEA was given to group I to evaluate the effect of PEA in neuropathic pain. Result: We studied 150 patients with PEA for 60 days in a dose of 354 mg orally three times (TDS) a day for first 10 days and then two times (BID) a day for 50 days. It is available in India by the name of Palmiges. PEA was associated with greater pain reduction in the study group compared to the placebo controlled group. The primary outcome measured was the mean pain reduction evaluated by VAS scale. Conclusion: PEA seems to be useful in the treatment of neuropathic / chronic pain and it is well tolerated in patients in study group. Palmiges PEA reduces the inflammation in neuropathic pain, which results in lowering/reduction of neuropathic pain. Controlled trials are further needed to prove efficacy and reliability and also to find out the adverse reaction associated with the drug.